Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

G. Fürstenberger; R. Von Moos; R. Lucas; B. Thürlimann; H. J. Senn; J. Hamacher; E. M. Boneberg

doi:10.1038/sj.bjc.6602952

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

G. Fürstenberger, R. Von Moos, R. Lucas, B. Thürlimann, H. J. Senn, J. Hamacher, E. M. Boneberg

Research output: Contribution to journal › Article › peer-review

211 Scopus citations

Abstract

Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34⁺/VEGFR-2⁺) as well as their progenitor cell population CDI33⁺/CD34⁺ and the population of CD34⁺ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

Original language	English (US)
Pages (from-to)	524-531
Number of pages	8
Journal	British Journal of Cancer
Volume	94
Issue number	4
DOIs	https://doi.org/10.1038/sj.bjc.6602952
State	Published - Feb 27 2006
Externally published	Yes

Keywords

Angiogenesis
Angiogenic factors
Breast cancer
Chemotherapy
Circulating endothelial cells

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6602952

Cite this

@article{88d947c4c7bf4226aa78ed0706200ee4,

title = "Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer",

abstract = "Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.",

keywords = "Angiogenesis, Angiogenic factors, Breast cancer, Chemotherapy, Circulating endothelial cells",

author = "G. F{\"u}rstenberger and {Von Moos}, R. and R. Lucas and B. Th{\"u}rlimann and Senn, {H. J.} and J. Hamacher and Boneberg, {E. M.}",

note = "Funding Information: This work was supported by grants of the Ostschweizerische Stiftung f{\"u}r klinische Krebsforschung (OSKK), St Gallen, Switzerland, of the Stiftung f{\"u}r Forschung in Tumordiagnostik und Pr{\"a}vention (STIFTUP), St Gallen, Switzerland, as well as by an award of the Schweizerische Arbeitsgemeinschaft f{\"u}r klinische Krebsforschung (SAKK), Bern, Switzerland. The excellent technical assistance of Karin Ryffel, Elisabeth B{\"a}chler and Dora Abbondandolo is greatly appreciated.",

year = "2006",

month = feb,

day = "27",

doi = "10.1038/sj.bjc.6602952",

language = "English (US)",

volume = "94",

pages = "524--531",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

AU - Fürstenberger, G.

AU - Von Moos, R.

AU - Lucas, R.

AU - Thürlimann, B.

AU - Senn, H. J.

AU - Hamacher, J.

AU - Boneberg, E. M.

N1 - Funding Information: This work was supported by grants of the Ostschweizerische Stiftung für klinische Krebsforschung (OSKK), St Gallen, Switzerland, of the Stiftung für Forschung in Tumordiagnostik und Prävention (STIFTUP), St Gallen, Switzerland, as well as by an award of the Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung (SAKK), Bern, Switzerland. The excellent technical assistance of Karin Ryffel, Elisabeth Bächler and Dora Abbondandolo is greatly appreciated.

PY - 2006/2/27

Y1 - 2006/2/27

N2 - Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

AB - Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

KW - Angiogenesis

KW - Angiogenic factors

KW - Breast cancer

KW - Chemotherapy

KW - Circulating endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=33344459620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344459620&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602952

DO - 10.1038/sj.bjc.6602952

M3 - Article

C2 - 16450002

AN - SCOPUS:33344459620

SN - 0007-0920

VL - 94

SP - 524

EP - 531

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 4

ER -

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this